Akums Drugs and Pharmaceuticals Limited AKUMS
NSE · India · Health Technology
INR 815.80-2.70 (-0.33%)
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Akums Drugs and Pharmaceuticals Ltd (BOM:544222) reports robust Q1 FY27 with 13.9% revenue growth, yet faces margin pressure in branded formulations and continued API losses.
Despite challenges in certain segments, Akums Drugs and Pharmaceuticals Ltd (BOM:544222) reports robust financial performance and outlines plans for international market expansion.
Despite a challenging quarter with declining revenues and margins, Akums Drugs and Pharmaceuticals Ltd (BOM:544222) focuses on strategic growth initiatives and European market penetration.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.